SCHEMBL2949633

SCHEMBL2949633

Nc1ccc(C(=O)Nc2ccccc2)cc1N

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC2 Q92769 3/20 0.63
HDAC1 Q13547 2/20 0.63
HDAC3 O15379 1/20 0.63
NCOR2 Q9Y618 1/20 0.63
PLAU P00749 2/20 0.61
PTPN1 P18031 2/20 0.59
F2 P00734 1/20 0.58
PLG P00747 1/20 0.58
PLAT P00750 1/20 0.58
KLKB1 P03952 1/20 0.58
KLK1 P06870 1/20 0.58
PRSS1 P07477 1/20 0.58
HDAC8 Q9BY41 2/20 0.58
HDAC6 Q9UBN7 2/20 0.58
JAK2 O60674 1/20 0.56
JAK1 P23458 1/20 0.56
NPC1 O15118 5/20 0.55
RAB9A P51151 5/20 0.55
ALDH1A1 P00352 2/20 0.55
LMNA P02545 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29364540 1.00 HDAC2 (0.63) HDAC2HDAC1HDAC3NCOR2PLAU
SCHEMBL27498643 0.86 HDAC2 (0.59) HDAC2HDAC1HDAC3NCOR2PLAU
SCHEMBL11200897 0.86 HDAC2 (0.59) HDAC2HDAC1HDAC3NCOR2PLAU
SCHEMBL24124203 0.86 HDAC1 (0.49) HDAC2HDAC1HDAC3NCOR2PLAU
SCHEMBL11325167 0.85 KMT2A (0.55) HDAC2HDAC1HDAC3NCOR2PLAU
SCHEMBL9116112 0.85 HDAC2 (0.58) HDAC2HDAC1HDAC3NCOR2PLAU
SCHEMBL6809737 0.85 KMT2A (0.60) HDAC2HDAC1HDAC3NCOR2PLAU
SCHEMBL11485725 0.85 HDAC2 (0.58) HDAC2HDAC1HDAC3NCOR2PLAU
SCHEMBL6810362 0.85 HDAC2 (0.62) HDAC2HDAC1HDAC3NCOR2PLAU
SCHEMBL6814507 0.85 MAPT (0.59) HDAC2HDAC1HDAC3NCOR2PLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1576093-A4 3-DEOXYGLUCOSONE AND SKIN DYNAMIS THERAPEUTICS INC (US) 2009-07-08 EP claimed
CN-101084235-A 3-deoxyglucosone and skin DYNAMIS THERAPEUTICS INC (US) 2007-12-05 CN claimed
US-20070065443-A1 Fructoseamine 3 kinase and the formation of collagen and elastin DYNAMIS THERAPEUTICS, INC. 2007-03-22 US claimed
EP-1576093-A2 3-DEOXYGLUCOSONE AND SKIN Dynamis Therapeutics, Inc. (US) 2005-09-21 EP claimed
US-20050159383-A1 Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) DYNAMIS THERAPEUTICS, INC. 2005-07-21 US claimed
US-20030219440-A1 3-deoxyglucosone and skin DYNAMIS THERAPEUTICS, INC. 2003-11-27 US claimed
WO-2003089601-A2 3-DEOXYGLUCOSONE AND SKIN DYNAMIS THERAPEUTICS, INC. (US) 2003-10-30 WO claimed
US-4381210-A Process for producing polyimide tubes NITTO ELECTRIC INDUSTRIAL CO., LTD. (JP) 1983-04-26 US claimed
WO-2026105418-A1 METHOD FOR MANUFACTURING SEMICONDUCTOR WAFER 三菱瓦斯化学株式会社 2026-05-21 WO disclosed
EP-4696736-A1 POLYIMIDE RESIN PRECURSOR, POLYIMIDE RESIN, AND POLYIMIDE FILM MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2026-02-18 EP disclosed
WO-2025121336-A1 POLYIMIDE RESIN 三菱瓦斯化学株式会社 2025-06-12 WO disclosed
WO-2025121335-A1 METHOD FOR PRODUCING POLYIMIDE VARNISH 三菱瓦斯化学株式会社 2025-06-12 WO disclosed
WO-2025121334-A1 POLYIMIDE RESIN 三菱瓦斯化学株式会社 2025-06-12 WO disclosed
WO-2025084155-A1 METHOD FOR PRODUCING POLYIMIDE RESIN 三菱瓦斯化学株式会社 2025-04-24 WO disclosed
US-5112989-A Process for producing unsaturated mono and dicarboxylic acid imide compound MATSUSHITA ELECTRIC WORKS LTD. (JP) 1992-05-12 US disclosed
EP-0387381-A1 Process for producing unsaturated dicarboxylic acid imide compound MATSUSHITA ELECTRIC WORKS, LTD. (JP) 1990-09-19 EP disclosed
US-4138581-A BRONCHODILATOR AGENTS, ADRENERGIC STIMULANTS STERLING DRUGS INC. (US) 1979-02-06 US disclosed
US-4138568-A NITRO-O-PHENYLENEDIAMINE, UREA, HALOBENZENE SOLVENT CIBA-GEIGY CORPORATION (US) 1979-02-06 US disclosed
US-4008195-A POLYESTER NITTO ELECTRIC INDUSTRIAL CO., LTD. (JA) 1977-02-15 US disclosed
US-3936404-A Aqueous baking varnishes from carboxylic polyester and carboxylic polyimide, and coated article NITTO ELECTRIC INDUSTRIAL CO., LTD. (JA) 1976-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070065443-A1 Fructoseamine 3 kinase and the formation of collagen and elastin FN3K, PDXK, COLGALT1 HDAC2 2294/4885HDAC1 1856/4885HDAC3 2331/4885
US-20030219440-A1 3-deoxyglucosone and skin DPM1, G6PD, UGGT1 HDAC2 1580/4885HDAC1 1097/4885HDAC3 713/4885
US-20050159383-A1 Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) AGER, GLA, GALE HDAC2 2770/4885HDAC1 2120/4885HDAC3 1137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.